GenFlow Bio
Organization
A biotechnology company developing gene therapies and longevity-related treatments, including programs targeting sarcopenia, glaucoma, and MASH.
What experts have said about GenFlow Bio
2 statements · 2 positive
A granted patent would materially increase GenFlow’s animal-health deal value.
“if we have a patent granted, issued, that will have a major impact on the value of the deal.”
Open the episode · S12 Ep2: The Sunday Roast featuring Genflow Biosciences, Energy Pathways and Buccaneer Energy #GENF #EPP #BUCE #INC #KEN #FMET #GMET #SVML #UOG #TGR #TAR #XTR #AFP #SRVLListen at 33:23
GenFlow’s animal-health deal valuation will exceed its market capitalization.
“the valuation of the deal will always be superior to our market cap.”
Open the episode · S12 Ep2: The Sunday Roast featuring Genflow Biosciences, Energy Pathways and Buccaneer Energy #GENF #EPP #BUCE #INC #KEN #FMET #GMET #SVML #UOG #TGR #TAR #XTR #AFP #SRVLListen at 35:16
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
2 episodes featuring GenFlow Bio
The Sunday Roast
Small caps weigh longevity science against energy and mining risk
The episode connects geopolitical uncertainty and macroeconomic pressure with the scientific, regulatory and financing hurdles facing small-cap companies.
Sep 13, 2026 · 1h 38m
The Sunday Roast
Mining deals and biotech catalysts shape a midsummer market review
The episode tests how financing, clinical evidence, national resilience and exploration milestones could reshape several small-cap stories through 2026.
Aug 2, 2026 · 1h 45m